Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Diageo plc (DEO) Price & Performance

ADMA Biologics IncTrade
Diageo plcTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Diageo plc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Diageo plc trades at $94.03 (market cap $53.75B). The key difference: Diageo plc is far larger — about 24.7× ADMA Biologics Inc's market cap, and Diageo plc pays a 3.42% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMADEO
Market Cap
$2.18B$53.75B
Sector
HealthTechnology
52-Week High
$20.38$115.33
52-Week Low
$7.60$72.47
Enterprise Value
$2.25B$73.25B
Dividend Yield
3.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Diageo plc

Diageo (DEO) trades at $96.35, up 3.83% with bullish technical signals from moving averages. The company reported mixed FY2026 results with a 2% organic sales decline but 2% operating profit growth, supported by cost savings. Analyst consensus leans positive with 48.65% buy ratings, though valuation metrics appear elevated with a P/E of 31.16. Recent news highlights a $1 billion cost-cutting plan and strategic focus on spirits and Guinness to drive turnaround.

The outlook is cautiously optimistic with management's restructuring program expected to improve margins and cash flow. Key risks include ongoing weakness in North American markets and competitive pressures. Wall Street sees potential upside with recent target increases, but investors should monitor execution of the turnaround plan amid challenging market conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Diageo plc

Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.

Read more on DEO